Last Updated : July 23, 2018
Details
FilesGeneric Name:
Trifluridine and Tipiracil
Project Status:
Complete
Therapeutic Area:
Metastatic Colorectal Cancer
Manufacturer:
Taiho Pharma Canada, Inc.
Brand Name:
Lonsurf
Project Line:
Reimbursement Review
Project Number:
PC0122-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
15 mg & 20 mg
Tumour Type:
Gastrointestinal
Indications:
Metastatic Colorectal Cancer
Funding Request:
For the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents
Pre Noc Submission:
Yes
Sponsor:
Taiho Pharma Canada, Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : July 23, 2018